✨ Free AI Report
Cyclacel Pharmaceuticals, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Cyclacel Pharmaceuticals, Inc.
Research Preview

Cyclacel Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops medicines for the treatment of cancer and other proliferative diseases. The firm is focused on developing cancer medicines bas...

Analyst-debate audio for Cyclacel Pharmaceuticals, Inc.

AskCyborg analysts argue the bull and bear cases for Cyclacel Pharmaceuticals, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Cyclacel Pharmaceuticals, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
4/ 10Mixed

Cyborg Score thesis

Early-stage oncology biotech with differentiated cell cycle mechanism; clinical progression provides validation but capital...

Read the full analyst-debate transcript →
Industry Oncology therapeutics development
3 named competitors
2 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: June 22, 2026
AI-Verified Research
30+ Page Report

Get the Latest Cyclacel Pharmaceuticals, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Cyclacel Pharmaceuticals, Inc. Overview

Pro stress-test →

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops medicines for the treatment of cancer and other proliferative diseases. The firm is focused on developing cancer medicines based on cell cycle, epigenetics and mitosis biology.

Strategic Profile

Pro stress-test →

Lead products include fadraciclib, a cyclin dependent kinase inhibitor (CDK) in Phase 1/2 clinical trial for solid tumors and in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia, and Plogosertib, a polo-like kinase inhibitor program in Phase 1/2 clinical trial for advanced leukemias and solid tumors. The company pursues a mechanism-targeted approach to oncology drug development.

Competitive Landscape

Pro stress-test →

Cyclacel competes in the crowded oncology space against established CDK inhibitor players (Novartis, Eli Lilly, others) and emerging PLK1-targeted therapeutics developers. Differentiation hinges on mechanism selectivity and precision patient stratification rather than first-to-market positioning.

Industry Context

Cyclacel Pharmaceuticals, Inc. operates in Oncology therapeutics development.

Key facts

Founded: 1996 · Headquarters: Berkeley Heights, New Jersey, United States · Employees: 11-50 · Revenue: N/A · Market cap: N/A

What the analysts stress-tested

The top findings that survived the multi-agent debate for Cyclacel Pharmaceuticals, Inc..

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Cyclacel Pharmaceuticals, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Palbociclib (Ibrance)Approved CDK4/6 inhibitor for breast cancer→Ribociclib (Kisqali)Approved CDK4/6 inhibitor for hormone receptor positive breast cancer→Venetoclax (Venclexta)BCL2 inhibitor approved for CLL and AML→

Compare Cyclacel Pharmaceuticals, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Cyclacel Pharmaceuticals, Inc. operates in Oncology therapeutics development. See how the rest of the sector scores on the Cyborg framework.

Browse Oncology therapeutics development research →
NEW · MCP server

Ask your AI assistant about Cyclacel Pharmaceuticals, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Cyclacel Pharmaceuticals, Inc. and its top competitor on Cyborg Score”
“What did Cyclacel Pharmaceuticals, Inc. do this quarter?”
“Is Cyclacel Pharmaceuticals, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Cyclacel Pharmaceuticals, Inc. do?+
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops medicines for the treatment of cancer and other proliferative diseases. The firm is focused on developing cancer medicines bas...
What is Cyclacel Pharmaceuticals, Inc.'s Cyborg Score?+
Cyclacel Pharmaceuticals, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Cyclacel Pharmaceuticals, Inc.'s main competitors?+
Named competitors include Palbociclib (Ibrance), Ribociclib (Kisqali), Venetoclax (Venclexta). The full competitive landscape is in the AskCyborg report.
How can I get the full Cyclacel Pharmaceuticals, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Cyclacel Pharmaceuticals, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Cyclacel Pharmaceuticals, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

Other strong performers across the analyst-debate framework. Click any to see their research report.

9Rasan Information Technology Company9Aritzia Inc.9Coherent Corp.9SanDisk Corporation9Zhongji Innolight Co., Ltd.9Cintas Corporation9Lockheed Martin Corporation9ASML Holding N.V.9Broadcom Inc.8Hamilton Insurance Group, Ltd.8Agility Global8Monogram Technologies Inc.8Smartoptics Group ASA8Sidetrade SA8Schweizerische Nationalbank8Funding Circle Holdings plc8BitFuFu Inc.8COMPASS Pathways plc